(Q34544937)

15 June 2018

3 references

27 September 2019

27 November 2019

13 December 2019

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. (English)

1 reference

15 June 2018

0 references

3 references

27 September 2019

27 November 2019

13 December 2019

1 reference

27 September 2019

3 references

27 September 2019

27 November 2019

13 December 2019

1 reference

27 November 2019

1 reference

13 December 2019

Matteo Ferrando

3

0 references

Giovanni Passalacqua

5

Giovanni Passalacqua

1 reference

PMC publication ID

5941977

15 June 2018

Giorgio Walter Canonica

6

Giorgio W Canonica

1 reference

15 June 2018

Francesca Puggioni

4

0 references

Diego Bagnasco

Diego Bagnasco

2

0 references

Gilda Varricchi

1

Gilda Varricchi

1 reference

15 June 2018

publication date

17 November 2016

1 reference

15 June 2018

Therapeutic advances in respiratory disease

1 January 2017

3 references

27 September 2019

27 November 2019

13 December 2019

4 references

15 June 2018

27 September 2019

27 November 2019

13 December 2019

11

1 reference

15 June 2018

issue

1

1 reference

15 June 2018

page(s)

40-45

1 reference

15 June 2018

Creative Commons Attribution-NonCommercial 3.0 Unported

copyright license

3 references

27 September 2019

27 November 2019

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies

13 December 2019

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5941977

Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5941977

The βc receptor family - Structural insights and their functional implications

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5941977

Type 2 innate lymphoid cells control eosinophil homeostasis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5941977

The consequences of not having eosinophils.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5941977

Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5941977

Mepolizumab and exacerbations of refractory eosinophilic asthma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5941977

Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5941977

Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5941977

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5941977

Interleukin 5 modifies histamine release and leukotriene generation by human basophils in response to diverse agonists

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5941977

Enhancement of human basophil histamine release by interleukin 5

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5941977

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

7 July 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465816673303

Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465816673303

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465816673303

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465816673303

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465816673303

Anti–IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465816673303

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465816673303

Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465816673303

Mepolizumab treatment in patients with severe eosinophilic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465816673303

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465816673303

Basophils express a type 2 cytokine profile on exposure to proteases from helminths and house dust mites

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465816673303

IL-5-mediated eosinophil survival requires inhibition of GSK-3 and correlates with β-catenin relocalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465816673303

Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465816673303

Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465816673303

Eosinophils in asthma--closing the loop or opening the door?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465816673303

Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5941977

Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti–IL-5 antibody SCH55700

27 October 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465816673303

Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys

21 January 2018

1 reference

12 December 2020

IL-5-mediated eosinophil survival requires inhibition of GSK-3 and correlates with beta-catenin relocalization

1 reference

12 December 2020

MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function

1 reference

12 December 2020

Analysis of the survival of mature human eosinophils: interleukin-5 prevents apoptosis in mature human eosinophils

1 reference

12 December 2020

Identifiers

DOI

10.1177/1753465816673303

1 reference

15 June 2018

PMC publication ID

5941977

1 reference

15 June 2018

PubMed publication ID

27856823

1 reference

15 June 2018